REGENXBIO Inc. (RGNX)

NASDAQ: RGNX · Real-Time Price · USD
9.61
+1.25 (14.95%)
At close: Jun 6, 2025, 4:00 PM
9.90
+0.29 (3.02%)
After-hours: Jun 6, 2025, 5:59 PM EDT
14.95%
Market Cap 482.04M
Revenue (ttm) 156.72M
Net Income (ttm) -157.69M
Shares Out 50.16M
EPS (ttm) -3.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,911,410
Open 8.42
Previous Close 8.36
Day's Range 8.32 - 9.78
52-Week Range 5.04 - 15.36
Beta 1.09
Analysts Strong Buy
Price Target 31.75 (+230.39%)
Earnings Date Jul 31, 2025

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 17, 2015
Employees 353
Stock Exchange NASDAQ
Ticker Symbol RGNX
Full Company Profile

Financial Performance

In 2024, REGENXBIO's revenue was $83.33 million, a decrease of -7.66% compared to the previous year's $90.24 million. Losses were -$227.10 million, -13.81% less than in 2023.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price forecast is $31.75, which is an increase of 230.39% from the latest price.

Price Target
$31.75
(230.39% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA d...

9 hours ago - Seeking Alpha

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.

1 day ago - Benzinga

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne All dose level 2 participants exceeded external natural history controls on all functional measures Bio...

1 day ago - PRNewsWire

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial ROCKVILLE, Md.

4 days ago - PRNewsWire

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

$150 million secured at closing extends cash runway into early 2027 REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) a...

18 days ago - PRNewsWire

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

PARAMUS, N.J. , May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.

23 days ago - PRNewsWire

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & CEO Steve Pakola - Chie...

24 days ago - Seeking Alpha

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

FDA assigns PDUFA target action date of November 9, 2025 RGX-121 on track to be the first gene therapy and one-time treatment for MPS II Partner Nippon Shinyaku to lead commercialization upon potentia...

24 days ago - PRNewsWire

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025  Additional Phase I/II functional data expected 1H 2...

25 days ago - PRNewsWire

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

ROCKVILLE, Md. , May 8, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New...

4 weeks ago - PRNewsWire

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. , May 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: BofA Securities Health Care Conference 2025 Presen...

4 weeks ago - PRNewsWire

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m.

5 weeks ago - PRNewsWire

5 Reasons To Buy Regenxbio Right Now

Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, wit...

2 months ago - Seeking Alpha

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Positive biomarker data in patient aged 1-3 add to consistent, robust microdystrophin and transduction levels across all treated ages Patient aged 3 years at dosing had expression level at 122.3% comp...

2 months ago - PRNewsWire

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & Chief Executive Offic...

3 months ago - Seeking Alpha

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand potent...

3 months ago - PRNewsWire

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

ROCKVILLE, Md. , March 10, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202 for the ...

3 months ago - PRNewsWire

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

ROCKVILLE, Md. , March 4, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced strategic partnership with Nippon Shinyaku.

3 months ago - PRNewsWire

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m.

3 months ago - PRNewsWire

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Goldman Sachs downgraded Regenxbio Inc RGNX, citing gene therapy's appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer longer-la...

4 months ago - Benzinga

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

ROCKVILLE, Md. , Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II...

4 months ago - PRNewsWire

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Partnership established with Nippon Shinyaku to develop RGX-121 and RGX-111 f...

Other symbols: AMD
5 months ago - Seeking Alpha

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets we...

5 months ago - Seeking Alpha

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing Nippon Shinyaku to lead commerc...

5 months ago - PRNewsWire

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO wil...

Other symbols: ABBV
5 months ago - PRNewsWire